Evidence map›Paper›PMID 38784605›Full record

ArticleOncology letters2024

Dynamics of the neutrophil‑to‑lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma.

Akifumi Kuwano, Masayoshi Yada, Yuta Koga, Kosuke Tanaka, Yoshihiro Ohishi, Akihide Masumoto, Kenta Motomura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Akifumi KuwanoDepartment of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.
Masayoshi YadaDepartment of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.
Yuta KogaDepartment of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.
Kosuke TanakaDepartment of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.
Yoshihiro OhishiDepartment of Diagnostic Pathology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.
Akihide MasumotoDepartment of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.
Kenta MotomuraDepartment of Hepatology, Aso Iizuka Hospital, Iizuka, Fukuoka 820-8505, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenvatinib is an approved therapy for advanced hepatocellular carcinoma (HCC). Recently, immune checkpoint inhibitors have been approved as frontline chemotherapies for HCC, and the tumor immune microenvironment (TIME) has been demonstrated to significantly affect HCC treatment. The neutrophil-to-lymphocyte ratio (NLR) is associated with the TIME, and the dynamics of the NLR are associated with prognosis or treatment efficacy in various cancer types. The present study investigated the dynamics of the TIME using the NLR in 101 patients with HCC treated with lenvatinib. Immunostaining for CD8

Indexed as

HCCimmune microenvironmentlenvatinibNLR

Identifiers

PMID38784605
PMCPMC11112146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.